Elon Musk’s Neuralink Implants Brain Chip in First Human 

Neuralink logo and Elon Musk photo are seen in this illustration taken, December 19, 2022. (Reuters)
Neuralink logo and Elon Musk photo are seen in this illustration taken, December 19, 2022. (Reuters)
TT

Elon Musk’s Neuralink Implants Brain Chip in First Human 

Neuralink logo and Elon Musk photo are seen in this illustration taken, December 19, 2022. (Reuters)
Neuralink logo and Elon Musk photo are seen in this illustration taken, December 19, 2022. (Reuters)

The first human patient has received an implant from brain-chip startup Neuralink on Sunday and is recovering well, the company's billionaire founder Elon Musk said.

"Initial results show promising neuron spike detection," Musk said in a post on the social media platform X on Monday.

Spikes are activity by neurons, which the National Institute of Health describes as cells that use electrical and chemical signals to send information around the brain and to the body.

The US Food and Drug Administration had given the company clearance last year to conduct its first trial to test its implant on humans, a critical milestone in the startup's ambitions to help patients overcome paralysis and a host of neurological conditions.

In September, Neuralink said it received approval for recruitment for the human trial.

The study uses a robot to surgically place a brain-computer interface (BCI) implant in a region of the brain that controls the intention to move, Neuralink said previously, adding that its initial goal is to enable people to control a computer cursor or keyboard using their thoughts alone.

The implants' "ultra-fine" threads help transmit signals in participants' brains, Neuralink has said.

The first product from Neuralink would be called Telepathy, Musk said in a separate post on X.

The startup's PRIME Study is a trial for its wireless brain-computer interface to evaluate the safety of the implant and surgical robot.

Neuralink did not immediately respond to a Reuters request for further details.

The company has faced calls for scrutiny regarding its safety protocols. Reuters reported earlier this month that the company was fined for violating US Department of Transportation (DOT) rules regarding the movement of hazardous materials.

The company was valued at about $5 billion last June, but four lawmakers in late November asked the US Securities and Exchange Commission to investigate whether Musk had misled investors about the safety of its technology after veterinary records showed problems with the implants on monkeys included paralysis, seizures and brain swelling.

Musk wrote in a social media post on Sept. 10 that "no monkey has died as a result of a Neuralink implant." He added that the company chose "terminal" monkeys to minimize risk to healthy ones.



SDAIA, KAUST Launch MiniGPT-Med Model to Help Doctors Diagnose Medical Radiology through AI

SDAIA, KAUST Launch MiniGPT-Med Model to Help Doctors Diagnose Medical Radiology through AI
TT

SDAIA, KAUST Launch MiniGPT-Med Model to Help Doctors Diagnose Medical Radiology through AI

SDAIA, KAUST Launch MiniGPT-Med Model to Help Doctors Diagnose Medical Radiology through AI

The Center of Excellence for Data Science and Artificial Intelligence at the Saudi Data and Artificial Intelligence Authority (SDAIA) and King Abdullah University of Science and Technology (KAUST) have introduced the MiniGPT-Med model.

The large multi-modal language model is designed to help doctors quickly and accurately diagnose medical radiology using artificial intelligence techniques.

Dr. Ahmed Alsinan, the Artificial Intelligence Advisor at the National Center for Artificial Intelligence and head of the scientific team at SDAIA, explained that the MiniGPT-Med model is capable of performing various tasks such as generating medical reports, answering medical visual questions, describing diseases, locating diseases, identifying diseases, and documenting medical descriptions based on entered medical images.

The model was trained on different medical images, including X-rays, CT scans, and MRIs.

The MiniGPT-Med model, derived from large-scale language models, is specifically tailored for medical applications and demonstrates significant versatility across different imaging methods, including X-rays, CT scans, and MRI. This enhances its utility in medical diagnosis.

Dr. Alsinan highlighted that the MiniGPT-Med model was developed collaboratively by artificial intelligence specialists from SDAIA and KAUST.

The model exhibits advanced performance in generating medical reports, achieving 19% higher efficiency than previous models. It serves as a general interface for radiology diagnosis, enhancing diagnostic efficiency across various medical imaging applications.